← boothcheck

ABT vs AMGN stock comparison

ABBOTT LABORATORIES vs Amgen Inc., two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.

Abbott and Amgen both file among drug makers, but Abbott is really a diversified medical company and Amgen a leveraged biotech. Amgen runs the higher operating margin, 31% to Abbott's 12, and posts an 85% return on equity, though that figure leans on a 6.8-to-1 debt-to-equity load more than on pure profitability. Abbott's 12% return on equity comes off a far more conservative balance sheet, and the two stocks price almost on top of each other, both near 25 times earnings. Both pay a dividend near 2.7%. Abbott is the steady, modestly priced diversifier; Amgen the higher-margin balance-sheet bet.

Comparison updated 2026-06-15.

ABT vs AMGN: the numbers

MetricABTAMGN
Price$93.93$363.37
Market cap$164.1B$197.7B
SectorDrug ManufacturersDrug Manufacturers
StageMatureMature
Implied growth (priced in)+9.6%+5.8%
P/E26.325.3
P/B3.1121.51
P/S3.645.31
EV/EBITDA20.816.1
Revenue growth+6.6%+9.0%
Operating margin12.1%30.9%
Net margin13.9%21.0%
Return on equity11.9%84.9%
Return on assets5.7%8.4%
Return on invested capital6.6%12.8%
FCF yield4.5%4.3%
Dividend yield2.6%2.7%
Debt / equity0.656.83
Current ratio1.391.26
Altman Z (solvency)7.166.21
Piotroski F (quality)6 / 95 / 9
Full ABT report → Full AMGN report →
Get boothcheck's read on ABT and AMGN, and what their prices are betting on, in your inbox. No hype, no spam.
Free. Informational only, not investment advice. Unsubscribe anytime.

Compare any two stocks

vs

The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.